Brca+ Breast Cancer: The Advent Of Parp Inhibitors

BRCA+ Breast Cancer: The Advent of PARP Inhibitors

Seminar Clips: PARP Inhibitors and BRRCA1/2 Cancers- Susan Domchek, MD | Stanford Cancer Institute

Stanford Cancer Institute

PARP Inhibitors for BRCA-Associated TNBC

What is a PARP Inhibitor? | Dana-Farber Cancer Institute | Science Illustrated

Dana-Farber Cancer Institute

Testing for BRCA Germline Mutations in the Clinic and the Mechanism of Action of PARP Inhibitors

Dr. Traina on PARP Inhibition in BRCA-Mutated Breast Cancer

Treating BRCA breast cancer with PARP inhibition

Future Role of PARP Inhibition in BRCA+ Breast Cancer

Dr. Litton on the Impact of PARP Inhibitors in Breast Cancer

PARPi for somatic BRCA1/2 and other DNA repair gene mutations in women with metastatic breast cancer

Distinguishing Between PARP Inhibitors in Breast Cancer

Overcoming resistance to PARP inhibition in ovarian cancer

Case 4: PARP Inhibitors for Treating BRCA+ Triple-Negative Breast Cancer

Targeted Oncology

PARP Inhibitors #Short

Yerbba – Breast Cancer

TALAVE: induction talazoparib with PARP inhibition in breast cancer

Talking with Patients about PARP Inhibitors for Breast Cancer

The France Foundation

Immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer

Managing metastatic breast cancer and beyond using PARP inhibitors

PARP Inhibitors for BRCA-Mutated TNBC

PARP-inhibitors: A New Generation of Cancer Drugs

Cambridge University